The Oncology Brothers and Patrick Forde, MBBCh, outline immunotherapy options for patients with non–small cell lung cancer and the role of PD-L1 in informing treatment decisions.
Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC
The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC
Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.